Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pulmatrix, Inc. (PULM : NSDQ)
 
 • Company Description   
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.

Number of Employees: 29

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.72 Daily Weekly Monthly
20 Day Moving Average: 13,969 shares
Shares Outstanding: 3.65 (millions)
Market Capitalization: $9.93 (millions)
Beta: 0.75
52 Week High: $7.50
52 Week Low: $2.63
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.17% -10.68%
12 Week -20.24% -25.95%
Year To Date -29.90% -36.23%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
99 HAYDEN AVENUE SUITE 390
-
LEXINGTON,MA 02421
USA		 ph: 781-357-2333
fax: 707-525-9906		 tim@lifesciadvisors.com http://www.pulmatrix.com
 
 • General Corporate Information   
Officers
Teofilo Raad - Chief Executive Officer; President and Director
Michael J. Higgins - Chairman
Peter Ludlum - Interim Chief Financial Officer
Richard Batycky - Director
Todd Bazemore - Director

Peer Information
Pulmatrix, Inc. (CORR.)
Pulmatrix, Inc. (RSPI)
Pulmatrix, Inc. (CGXP)
Pulmatrix, Inc. (BGEN)
Pulmatrix, Inc. (GTBP)
Pulmatrix, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 74584P301
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/23
Next Expected EPS Date: 08/14/23
Share - Related Items
Shares Outstanding: 3.65
Most Recent Split Date: 3.00 (0.05:1)
Beta: 0.75
Market Capitalization: $9.93 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.23 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.94 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/14/23  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.37
Price/Cash Flow: -
Price / Sales: 1.55
EPS Growth
vs. Year Ago Period: 19.21%
vs. Previous Quarter: -7.02%
Sales Growth
vs. Year Ago Period: 29.22%
vs. Previous Quarter: -12.24%
ROE
03/31/23 - -55.65
12/31/22 - -51.32
09/30/22 - -46.03
ROA
03/31/23 - -42.37
12/31/22 - -39.43
09/30/22 - -35.70
Current Ratio
03/31/23 - 6.93
12/31/22 - 7.60
09/30/22 - 6.84
Quick Ratio
03/31/23 - 6.93
12/31/22 - 7.60
09/30/22 - 6.84
Operating Margin
03/31/23 - -285.66
12/31/22 - -310.26
09/30/22 - -387.03
Net Margin
03/31/23 - -285.66
12/31/22 - -310.26
09/30/22 - -387.03
Pre-Tax Margin
03/31/23 - -285.66
12/31/22 - -310.26
09/30/22 - -387.03
Book Value
03/31/23 - 7.40
12/31/22 - 8.55
09/30/22 - 10.35
Inventory Turnover
03/31/23 - -
12/31/22 - -
09/30/22 - -
Debt-to-Equity
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
Debt-to-Capital
03/31/23 - 0.00
12/31/22 - 0.00
09/30/22 - 0.00
 

Powered by Zacks Investment Research ©